Abstract: The present invention is based on the identification of a number of genetic markers that are associated with susceptibility to Paget's disease of bone (PDB). This invention provides details of markers and nucleotide sequences as well as associated proteins/peptides and/or compositions and methods, for use in treating, preventing and/or detecting/diagnosing PDB and/or a susceptibility/predisposition thereto.

Abstract: The present invention provides a method for detecting autoantibodies to osteoprotegerin (OPG). The method comprises the step of providing a biological sample from a subject with, or at risk of osteoporosis and detecting whether or not any antibodies against osteoprotegerin (OPG) are present in said sample. In addition the invention provides methods useful in aiding the diagnosis/prognosis and/or therapeutic regimen for autoimmune and/or vascular disease in general.

Abstract: The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R1—O-A-O—R2, wherein: A is a C2-10 alkylene group; R1 is independently a first hydroxy protecting group (e.g., an ester group); and, R2 is independently —H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption.

Abstract: The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, Ralk, —ORO, and -Q are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

Abstract: The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae: (1) (2) wherein: Ar1 is independently a biphenyl, phenanthryl, fluorenyl, or carbazolyl, and is optionally substituted; Ralk is independently a C2-10alkylene group, and is optionally substituted; —ORO, if present, is independently —OH or —ORK; —ORK, if present, is independently selected from: —O—RK1; —O—C(?O)RK2; —O—C(?O)ORK3; —O—S(?O)2ORK4; Q is independently —OH or —OROT; wherein: —OROT, if present, is independently selected from: —O—RE1; —O—C(?O)—RE2; —O—C(?O)—O—RE3; —O—C(?O)—O—SO3RE4; —O—C(?O)—O—(CH2)n—COORE5; —O—C(?O)—(CH2)n—NRN1RN2; —O—C(?O)—(CH2)n—NH—C(?O)RE6; —O—C(?O)—(CH2)n—C(?O)—NRN3RN4; —O—P(?O)(ORE7)(ORE8); —O—RPA; RPA, if present, is an organic group which incorporates a phosphonic acid group; with the proviso that if —OROT is —O—RE1, then RE1 is

Abstract: The present invention pertains to certain ketones and reduced ketones and derivatives thereof which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption, and more particularly to compounds of the formulae and pharmaceutically acceptable salts, amides, esters, and ethers thereof, wherein: Ar1, Ralk, —ORO, and -Q are as defined herein: The present invention also pertains to pharmaceutical compositions comprising such compounds. The compounds inhibit osteoclast survival, formation, and/or activity, and inhibit conditions mediated by osteoclasts and/or characterised by bone resorption, and are useful in the treatment of bone disorders such as osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, aseptic loosening of prosthetic implants, and the like; and/or in the treatment of conditions associated with inflammation or activation of the immune system.

Abstract: The present invention pertains to certain alkane diol derivatives (including, e.g., mono- and di-esters) of the formula R1—O-A-O—R2, wherein: A is a C2-10 alkylene group; R1 is independently a first hydroxy protecting group (e.g., an ester group); and, R2 is independently —H or a second hydroxy protecting group (e.g., an ester group); and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrug thereof, which, inter alia, inhibit osteoclast survival, formation, and/or activity; and/or inhibit bone resorption.